Evidence map›Paper›PMID 38606424›Full record

ArticleClinical and molecular hepatology2024

Optimizing off-treatment outcome predictions: The potential of time-varying HBcrAg and the need for more research.

Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu

Abstract read
In one paragraph

Article in Clinical and molecular hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ying-Nan TsaiDivision of Gastroenterology and Hepatology, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan.
Jia-Ling WuDepartment of Public Health, National Cheng Kung University, College of Medicine, Tainan, Taiwan.
Yao-Chun HsuSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.

Funding

Gilead Sciences
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hepatitis B Core AntigensHepatitis B Surface AntigensAntiviral AgentsBiomarkersDNA, ViralHepatitis B e AntigensHepatitis B virusHumansTreatment OutcomeAntiviral AgentsBiomarkersDNA, ViralHepatitis B Core AntigensHepatitis B e AntigensHepatitis B Surface AntigensAntiviral treatmentChronic hepatitis BHepatitis B core-related antigen

Identifiers

PMID38606424
PMCPMC11016472

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.